Open-Label Placebo for Functional Dyspepsia

Early Phase 1

Terminated

• Conditions: Dyspepsia
• Interventions: Drug: Placebos

• Registration Number: NCT03745781
• Lead Sponsor: Beth Israel Deaconess Medical Center

Brief Summary

The study is evaluating the efficacy of open-label placebo for the treatment of functional dyspepsia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-11-14
• Study First Submitted QC: 2018-11-16
• Study First Posted: 2018-11-19
• Study Start: 2018-12-01
• Primary Completion: 2019-10-07
• Study Completion: 2019-10-07
• Status Verified: 2020-05
• Last Update Submitted: 2020-05-04
• Last Update Posted: 2020-05-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• Functional Dyspepsia

Exclusion Criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
open-label placebo	Placebos	open-label placebo

Primary Outcome Measures

Name	Time	Method
dyspepsia severity on a VAS from 0-100	3 weeks	How severe have your dyspepsia symptoms been over the past 7 days (on a VAS from 0-100)?

Trial Locations

Locations (1)

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States